Fate Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Fate Therapeutics Inc (FATE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Fate Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 6M vs 120,590M combined for its competitors (0.0% combined share).
- Scale: Fate Therapeutics Inc ranks #84 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.04M compares with $1.66M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Fate Therapeutics Inc vs. its Competitors, Q3 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Fate Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Fate Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Fate Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (11) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Fate Therapeutics Inc's competitor groups requires a Commercial License.
Fate Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Fate Therapeutics Inc | - | - | - | Yes |
| Competitors combined (53) | ||||
| High-Confidence Competitors (23) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FATE Stock Performance relative to its Competitors
FATE Stock Performance relative to High-Confidence Competitors
FATE Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 5 | Revolution Medicines Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Fate Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Fate Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Fate Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Fate Therapeutics Inc |
165.70 | 6.49 |
 Amgen Inc |
255,014.76 | 38,903.00 |
 Gilead Sciences Inc |
210,105.45 | 30,988.00 |
 Bristol myers Squibb Company |
127,942.96 | 50,033.00 |
 Moderna Inc |
92,077.30 | 2,228.00 |
 Revolution Medicines Inc |
37,191.09 | 29.51 |
| SUBTOTAL | 750,846.70 | 124,698.22 |
Sign in to see all competitors of Fate Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Fate Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Fate Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Fate Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nkgen Biotech Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Sana Biotechnology, Inc. | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Regeneron Pharmaceuticals, Inc. | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Kite Pharma | Company report | 85% |
| Bristol-Myers Squibb Company | Company report | 85% |
| Novartis AG | Company report | 85% |
| Nkarta, Inc. | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Poseida Therapeutics, Inc. | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| 2seventy bio, Inc. | Company report | 85% |
| Precision Biosciences, Inc. | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Sanofi SA | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| NantKwest, Inc. | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Quoin Pharmaceuticals Ltd | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Celyad Oncology Sa | Company report | 85% |
| Tcr2 Therapeutics Inc | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Athersys Inc | Company report | 85% |
| Century Therapeutics inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Surface Oncology Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Gamida Cell Ltd | Company report | 85% |
| Geron Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Fate Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Fate Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Verastem Inc | Research Developing and Commercialization Drugs Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Fate Therapeutics Inc .
Fate Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Fate Therapeutics Inc | 166 | 40,317 | -772,876 |
| Amgen Inc | 255,015 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 210,105 | 1,822,824 | -227,235 |
| Bristol myers Squibb Company | 127,943 | 1,539,477 | 284,338 |
| Moderna Inc | 92,077 | 474,043 | -670,426 |
| Revolution Medicines Inc | 37,191 | 33,420 | -2,002,588 |
| PEERS TOTAL | 750,681 | 1,662,867 | 88,106 |
Sign in to see all peers for Fate Therapeutics Inc .
Fate Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Immunitybio inc | United States 99.79 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Fate Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Fate Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Fate Therapeutics Inc ranks #84 of 157 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,442, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 255,794 | 27.04 % |
| 2 | Gilead Sciences Inc | 212,826 | 22.50 % |
| 3 | Moderna Inc | 95,046 | 10.05 % |
| 4 | Argenx Se | 64,522 | 6.82 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 84 | Fate Therapeutics Inc | 175 | 0.02 % |
Market cap and industry share for the rest of Fate Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Fate Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 79 | Quince Therapeutics Inc | 235 | - |
| 80 | Precision Biosciences Inc | 232 | 49.50 % |
| 81 | Cabaletta Bio Inc | 209 | -44.13 % |
| 82 | Compugen Ltd | 196 | 21.51 % |
| 83 | Invivyd Inc | 1,234 | 12.3% |
| 84 | Fate Therapeutics Inc | 175 | 29.91 % |
| 85 | Zura Bio Limited | 1,234 | 12.3% |
| 86 | Sutro Biopharma Inc | 1,234 | 12.3% |
| 87 | Artiva Biotherapeutics Inc | 1,234 | 12.3% |
| 88 | Prokidney Corp | 1,234 | 12.3% |
| 89 | Entera Bio Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Fate Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-12. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Fate Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 1.9x | 5.1x | -3.2x |
| Return on Equity | -73.92 % | industry aggregate | -67.85 % |
| Return on Invested Capital | -34.73 % | -11.27 % (avg) | -23.46 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Fate Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 15.44 % | 125.32 % | 194.33 % | 77.66 % | 72.44 % | -34.03 % | -78.55 % | -51.24 % |
| Operating Margin | -1,415.44 % | -943.14 % | -407.47 % | -388.56 % | -320.23 % | - | - | - |
| Return on Invested Capital | -27.33 % | -23.33 % | -13.96 % | -12.97 % | -25.87 % | -22.59 % | -27.88 % | -29.52 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Fate Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Fate Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Fate Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,442 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Fate Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Fate Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Fate Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Fate Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 67.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (59.60 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Fate Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Fate Therapeutics Inc | 2.15 | 5.23 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Revolution Medicines Inc | 1.35 | 7.28 | 0.07 |
Sign in to see all peers for Fate Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Fate Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Fate Therapeutics Inc | Q3 2026 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Revolution Medicines Inc | Q2 2026 | - | - |
| PEERS TOTAL | +8.3 % | +21.6 % |
Sign in to see all peers for Fate Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Fate Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Fate Therapeutics Inc | Q3 2026 | - | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Revolution Medicines Inc | Q2 2026 | - | -69.3 % |
Sign in to see all peers for Fate Therapeutics Inc .
Fate Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Fate Therapeutics Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Moderna Inc | - | - | - |
| Revolution Medicines Inc | - | - | - |
Sign in to see all peers for Fate Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Fate Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Fate Therapeutics Inc | - | 25.53 |
| Amgen Inc | 27.08 | 6.56 |
| Gilead Sciences Inc | - | 6.78 |
| Bristol myers Squibb Company | 13.81 | 2.56 |
| Moderna Inc | - | 41.33 |
| Revolution Medicines Inc | - | 1,260.29 |
| PEERS AVERAGE | 115.83 | 6.02 |
Sign in to see all peers for Fate Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.